MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression

Oncogene

Volumn 32, Issue 24, 2013, Pages 2984-2991

  Kappelmann, M ^a   Kuphal, S ^a   Meister, G ^a   Vardimon, L ^b   Bosserhoff, A K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

c Jun; malignant melanoma; migration; miRNA; post transcriptionally; protein expression

Indexed keywords

LUCIFERASE; MESSENGER RNA; MICRORNA; MICRORNA 125B; MICRORNA 527; PROTEIN C JUN; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDIATOR; MELANOCYTE; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REPORTER GENE; TUMOR CELL LINE; TUMOR GROWTH;

BASE SEQUENCE; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICRORNAS; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION, GENETIC;

EID: 84879416696     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.307     Document Type: Article

References (45)

1. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-868.
2. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumor-igenesis. Oncogene 2001; 20: 2401-2412.
3. Weiss C, Bohmann D. Deregulated repression of c-Jun provides a potential link to its role in tumorigenesis. Cell Cycle 2004; 3: 111-113.
4. Spangler B, Vardimon L, Bosserhoff AK, Kuphal S. Post-transcriptional regulation controlled by E-cadherin is important for c-Jun activity in melanoma. Pigment Cell Melanoma Res 2011; 24: 148-164.
5. Kovary K, Bravo R. The jun and fos protein families are both required for cell cycle progression in fibroblasts. Mol Cell Biol 1991; 11: 4466-4472.
6. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20: 2390-2400.
7. Gebauer F, Hentze MW. Molecular mechanisms of translational control. Nat Rev Mol Cell Biol 2004; 5: 827-835.
8. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004; 431: 343-349.
9. Vasudevan S. Posttranscriptional upregulation by MicroRNAs. Wiley Interdiscip Rev RNA 2012; 3: 311-330.
10. Papaconstantinou I, Karakatsanis A, Gazouli M, Polymeneas G, Voros D. The role of microRNAs in liver cancer. Eur J Gastroenterol Hepatol 2012; 24: 223-228.
11. Fang YX, Xue JL, Shen Q, Chen J, Tian L. miR-7 inhibits tumor growth and metastasis by targeting the PI3K/AKT pathway in hepatocellular carcinoma. Hepatology 2012; 55: 1852-1862.
12. Le XF, Merchant O, Bast RC, Calin GA. The roles of micrornas in the cancer invasion-metastasis cascade. Cancer Microenviron 2010; 3: 137-147.
13. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene 2006; 25: 6170-6175.
14. Mueller DW, Bosserhoff AK. Role of miRNAs in the progression of malignant melanoma. Br J Cancer 2009; 101: 551-556.
15. Howell Jr PM, Li X, Riker AI, Xi Y. MicroRNA in melanoma. Ochsner J 2010; 10: 83-92.
16. Deng Y, Deng H, Bi F, Liu J, Bemis LT, Norris D et al. MicroRNA-137 targets carboxyl-terminal binding protein 1 in melanoma cell lines. Int J Biol Sci 2011; 7: 133-137.
17. Ender C, Meister G. Argonaute proteins at a glance. J Cell Sci 2010; 123: 1819-1823.
18. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 2003; 100: 9779-9784.
19. Janga SC, Vallabhaneni S. MicroRNAs as post-transcriptional machines and their interplay with cellular networks. Adv Exp Med Biol 2011; 722: 59-74.
20. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30: 460-471.
21. Rigoutsos I. New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. Cancer Res 2009; 69: 3245-3248.
22. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
23. Chen J, Feilotter HE, Pare GC, Zhang X, Pemberton JG, Garady C et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 2010; 176: 2520-2529.
24. Xu Y, Brenn T, Brown ER, Doherty V, Melton DW. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer 2012; 106: 553-561.
25. Poser I, Tatzel J, Kuphal S, Bosserhoff AK. Functional role of MIA in melanocytes and early development of melanoma. Oncogene 2004; 23: 6115-6124.
26. Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA et al. Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol 2009; 34: 1481-1489.
27. Shoo BA, Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino-and Native-American populations. Semin Cutan Med Surg 2009; 28: 96-102.
28. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
29. Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 2009; 129: 1740-1751.
30. Philippidou D, Schmitt M, Moser D, Margue C, Nazarov PV, Muller A et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 2010; 70: 4163-4173.
31. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
32. Glud M, Rossing M, Hother C, Holst L, Hastrup N, Nielsen FC et al. Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res 2010; 20: 479-484.
33. Glud M, Manfe V, Biskup E, Holst L, Dirksen AM, Hastrup N et al. MicroRNA miR-125b induces senescence in human melanoma cells. Melanoma Res 2011; 21: 253-256.
34. Poser I, Bosserhoff AK. Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol 2004; 19: 173-188.
35. Libermann TA, Zerbini LF. Targeting transcription factors for cancer gene therapy. Curr Gene Ther 2006; 6: 17-33.
36. Spangler B, Kappelmann M, Schittek B, Meierjohann S, Vardimon L, Bosserhoff AK et al. ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma. Int J Cancer, 2012; 130: 2801-2811.
37. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
38. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
39. Katiyar S, Casimiro MC, Dettin L, Ju X, Wagner EF, Tanaka H et al. C-jun inhibits mammary apoptosis in vivo. Mol Biol Cell 2010; 21: 4264-4274.
40. Braig S, Bosserhoff A-K. Death inducer-obliterator 1 (Dido1) is a BMP target gene and promotes BMP-induced melanoma progression. Oncogene 2013; 32: 837-848.
41. Jacob K, Wach F, Holzapfel U, Hein R, Lengyel E, Buettner R et al. In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid. Melanoma Res 1998; 8: 211-219.
42. Polak P, Oren A, Ben Dror I, Steinberg D, Sapoznik S, Arditi-Duvdevany A et al. The cytoskeletal network controls c-Jun translation in a UTR-dependent manner. Oncogene 2006; 25: 665-676.
43. Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK. Bone mor-phogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 2005; 65: 448-456.
44. Braig S, Wallner S, Junglas B, Fuchshofer R, Bosserhoff AK. CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br J Cancer 2011; 105: 231-238.
45. Schmid R, Schiffner S, Opolka A, Grassel S, Schubert T, Moser M et al. Enhanced cartilage regeneration in MIA/CD-RAP deficient mice. Cell Death Dis 2010; 1: e97.